ARCUTIS BIOTHERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Payments to Acquire Debt Securities, Available-for-sale of $127.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $65.59M, a 97.85% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $62.15M, a 10.77% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $89.18M, a 412.56% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $68.54M, a 1103.79% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $246.99M, a 3.07% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $254.82M, a 12.83% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $225.84M, a 45.63% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $415.39M, a 42.01% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $127.74M 10-Q · filed 2026-08-05 | $216.92M derived: sum of 3 quarters · filed 2026-08-05 | $285.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $62.15M 10-Q · filed 2026-05-06 | $151.33M derived: sum of 2 quarters · filed 2026-05-06 | $219.88M derived: sum of 3 quarters · filed 2026-05-06 | $253.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $89.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $157.72M derived: sum of 2 quarters · filed 2026-02-25 | $190.88M derived: sum of 3 quarters · filed 2026-08-05 | $246.99M 10-K · filed 2026-02-25 |
| 2025-09-30 | $68.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $101.70M derived: sum of 2 quarters · filed 2026-08-05 | $157.81M 10-Q · filed 2025-10-28 | $175.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $33.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $89.26M 10-Q · filed 2026-08-05 | $106.66M derived: sum of 3 quarters · filed 2026-08-05 | $112.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $56.11M 10-Q · filed 2026-05-06 | $73.51M derived: sum of 2 quarters · filed 2026-05-06 | $79.20M derived: sum of 3 quarters · filed 2026-05-06 | $204.98M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $23.09M derived: sum of 2 quarters · filed 2026-02-25 | $148.87M derived: sum of 3 quarters · filed 2026-02-25 | $254.82M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $131.47M derived: sum of 2 quarters · filed 2025-10-28 | $237.42M 10-Q · filed 2025-10-28 | $355.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $125.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $231.73M 10-Q · filed 2025-08-06 | $349.91M derived: sum of 3 quarters · filed 2026-02-25 | $372.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $105.95M 10-Q · filed 2025-05-06 | $224.13M derived: sum of 2 quarters · filed 2026-02-25 | $246.52M derived: sum of 3 quarters · filed 2026-02-25 | $292.13M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $118.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $140.57M derived: sum of 2 quarters · filed 2026-02-25 | $186.17M derived: sum of 3 quarters · filed 2026-02-25 | $225.84M 10-K · filed 2026-02-25 |
| 2023-09-30 | $22.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $67.99M derived: sum of 2 quarters · filed 2024-11-06 | $107.66M 10-Q · filed 2024-11-06 | $145.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $45.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $85.27M 10-Q · filed 2024-08-14 | $123.36M derived: sum of 3 quarters · filed 2025-02-25 | $364.92M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $39.67M 10-Q · filed 2024-05-14 | $77.75M derived: sum of 2 quarters · filed 2025-02-25 | $319.31M derived: sum of 3 quarters · filed 2025-02-25 | $399.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $38.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $279.64M derived: sum of 2 quarters · filed 2025-02-25 | $359.88M derived: sum of 3 quarters · filed 2025-02-25 | $415.39M 10-K · filed 2025-02-25 |
| 2022-09-30 | $241.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $321.80M derived: sum of 2 quarters · filed 2023-11-03 | $377.30M 10-Q · filed 2023-11-03 | $425.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $80.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $135.75M 10-Q · filed 2023-08-08 | $183.99M derived: sum of 3 quarters · filed 2024-02-27 | $216.38M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $55.50M 10-Q · filed 2023-05-09 | $103.74M derived: sum of 2 quarters · filed 2024-02-27 | $136.14M derived: sum of 3 quarters · filed 2024-02-27 | $348.01M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $48.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $80.63M derived: sum of 2 quarters · filed 2024-02-27 | $292.51M derived: sum of 3 quarters · filed 2024-02-27 | $292.51M 10-K · filed 2024-02-27 |
| 2021-09-30 | $32.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $244.27M derived: sum of 2 quarters · filed 2022-11-08 | $244.27M 10-Q · filed 2022-11-08 | $344.01M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $211.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $211.88M 10-Q · filed 2022-08-04 | $311.62M derived: sum of 3 quarters · filed 2023-02-28 | $428.22M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $99.74M derived: sum of 2 quarters · filed 2023-02-28 | $216.34M derived: sum of 3 quarters · filed 2023-02-28 | $243.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $99.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $216.34M derived: sum of 2 quarters · filed 2023-02-28 | $243.82M derived: sum of 3 quarters · filed 2023-02-28 | $279.10M 10-K · filed 2023-02-28 |
| 2020-09-30 | $116.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $144.08M derived: sum of 2 quarters · filed 2021-11-04 | $179.36M 10-Q · filed 2021-11-04 | $217.30M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $27.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $62.76M 10-Q · filed 2021-08-05 | $100.70M derived: sum of 3 quarters · filed 2022-02-22 | $100.70M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $35.28M 10-Q · filed 2021-05-06 | $73.22M derived: sum of 2 quarters · filed 2022-02-22 | $73.22M derived: sum of 3 quarters · filed 2022-02-22 | $84.43M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $37.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $37.93M derived: sum of 2 quarters · filed 2022-02-22 | $49.14M derived: sum of 3 quarters · filed 2022-02-22 | $60.83M 10-K · filed 2022-02-22 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $11.21M derived: sum of 2 quarters · filed 2020-11-05 | $22.90M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $11.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $22.90M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $11.69M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $11.53M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |